Literature DB >> 25956486

Topical Delivery of 5-Fluorouracil from Pheroid™ Formulations and the In Vitro Efficacy Against Human Melanoma.

Tawona N Chinembiri1, Minja Gerber1, Lissinda du Plessis1, Jan du Preez1, Jeanetta du Plessis2.   

Abstract

Drug delivery vehicles can influence the topical delivery and the efficacy of an active pharmaceutical ingredient (API). In this study, the influence of Pheroid™ technology, which is a unique colloidal drug delivery system, on the skin permeation and antimelanoma efficacy of 5-fluorouracil were investigated. Lotions containing Pheroid™ with different concentrations of 5-fluorouracil were formulated then used in Franz cell skin diffusion studies and tape stripping. The in vitro efficacy of 5-fluorouracil against human melanoma cells (A375) was investigated using a flow cytometric apoptosis assay. Statistically significant concentrations of 5-fluorouracil diffused into and through the skin with Pheroid™ formulations resulting in an enhanced in vitro skin permeation from the 4.0% 5-fluorouracil lotion (p < 0.05). The stratum corneum-epidermis and epidermis-dermis retained 5-fluorouracil concentrations of 2.31 and 6.69 μg/ml, respectively, after a diffusion study with the 4.0% Pheroid™ lotion. Subsequent to the apoptosis assay, significant differences were observed between the effect of 13.33 μg/ml 5-fluorouracil in Pheroid™ lotion and the effects of the controls. The results obtained suggest that the Pheroid™ drug delivery system possibly enhances the flux and delivery of 5-fluorouracil into the skin. Therefore, using Pheroid™ could possibly be advantageous with respect to topical delivery of 5-fluorouracil.

Entities:  

Keywords:  A375 cells; cell culture; flow cytometry; melanoma; permeation enhancer

Mesh:

Substances:

Year:  2015        PMID: 25956486      PMCID: PMC4666243          DOI: 10.1208/s12249-015-0328-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  20 in total

Review 1.  Approaches for breaking the barriers of drug permeation through transdermal drug delivery.

Authors:  Amit Alexander; Shubhangi Dwivedi; Tapan K Giri; Swarnlata Saraf; Shailendra Saraf; Dulal Krishna Tripathi
Journal:  J Control Release       Date:  2012-10-10       Impact factor: 9.776

2.  Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism.

Authors:  Wen Liu; Xiaoling Li; Yum-Shing Wong; Wenjie Zheng; Yibo Zhang; Wenqiang Cao; Tianfeng Chen
Journal:  ACS Nano       Date:  2012-07-26       Impact factor: 15.881

3.  Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis.

Authors:  Iqrar Ali Alvi; Jitender Madan; Dinesh Kaushik; Satish Sardana; Ravi Shankar Pandey; Asgar Ali
Journal:  Anticancer Drugs       Date:  2011-09       Impact factor: 2.248

4.  Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery.

Authors:  N S Chandrashekar; R H Shobha Rani
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

5.  Penetration enhancer-containing vesicles: composition dependence of structural features and skin penetration ability.

Authors:  M Manconi; C Caddeo; C Sinico; D Valenti; M C Mostallino; S Lampis; M Monduzzi; A M Fadda
Journal:  Eur J Pharm Biopharm       Date:  2012-08-13       Impact factor: 5.571

6.  Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study.

Authors:  Richa Puri; Subheet Jain
Journal:  Anticancer Drugs       Date:  2012-10       Impact factor: 2.248

7.  Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer.

Authors:  Donatella Paolino; Donato Cosco; Rita Muzzalupo; Elena Trapasso; Nevio Picci; Massimo Fresta
Journal:  Int J Pharm       Date:  2007-11-28       Impact factor: 5.875

8.  Percutaneous delivery of econazole using microemulsion as vehicle: formulation, evaluation and vesicle-skin interaction.

Authors:  Shumin Ge; Yuanyuan Lin; Haoyang Lu; Qi Li; Jian He; Bao Chen; Chuanbin Wu; Yuehong Xu
Journal:  Int J Pharm       Date:  2014-02-12       Impact factor: 5.875

9.  Fluorouracil in the environment: analysis, occurrence, degradation and transformation.

Authors:  Tina Kosjek; Silva Perko; Dušan Žigon; Ester Heath
Journal:  J Chromatogr A       Date:  2013-03-25       Impact factor: 4.759

10.  Differential effects of 5-fluorouracil on human skin melanocytes and malignant melanoma cells in vitro.

Authors:  T Tsuji; M A Karasek
Journal:  Acta Derm Venereol       Date:  1986       Impact factor: 4.437

View more
  3 in total

1.  Pharmaceutical Development of 5-Fluorouracil-Eluting Stents for the Potential Treatment of Gastrointestinal Cancers and Related Obstructions.

Authors:  Mohammad Arafat; Yunmei Song; Kyle Brewer; Paris Fouladian; Ankit Parikh; Hugo Albrecht; Anton Blencowe; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2021-04-09       Impact factor: 4.162

Review 2.  Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures.

Authors:  Nazeer Hussain Khan; Maria Mir; Lei Qian; Mahnoor Baloch; Muhammad Farhan Ali Khan; Asim-Ur- Rehman; Ebenezeri Erasto Ngowi; Dong-Dong Wu; Xin-Ying Ji
Journal:  J Adv Res       Date:  2021-06-16       Impact factor: 10.479

3.  Weak complexation of 5-fluorouracil with β-cyclodextrin, carbonate, and dianhydride crosslinked β-cyclodextrin: in vitro and in silico studies.

Authors:  Hadeia Mashaqbeh; Rana Obaidat; Nizar A Al-Shar'i; Tamam El-Elimat; Soraya Alnabulsi
Journal:  Res Pharm Sci       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.